Recent animal and human neuroimaging studies suggest that antipsychotic medications are potentially toxic to cortical brain structures. However, the human studies have not been placebo-controlled and cannot establish causality. Also, some studies suggest that antipsychotics are actually protective against structural brain changes associated with untreated psychotic disorders. With the growing number of younger and older patients receiving antipsychotics, determining the overall effect of these medications on brain structure is a public health imperative. For ethical reasons, this question cannot be resolved in patients with schizophrenia. We are proposing to conduct a pre/post MRI/DTI neuroimaging study in the context of STOP- PD II, a newly NIMH-funded randomized, placebo-controlled trial of olanzapine in the continuation/maintenance treatment of major depression with psychotic features ("psychotic depression", PD). The main aims of this application are to assess brain changes in gray and white matter associated with olanzapine treatment. Using a mixed model regression analysis, we will compare changes in brain structure and connectivity over time in patients in whom olanzapine has been continued or discontinued. We hypothesize that, compared to placebo, continuing treatment with olanzapine will be associated with: cortical thinning throughout all lobes;increase in striatal volumes;reductions in white matter microstructure;and no change in surface area or hippocampal and amygdala volumes. Our application leverages the clinical infrastructure (i.e., screening, recruitment, treatment, and clinical monitoring) provided by STOP-PD II: 152 subjects who achieve remission after 12 weeks of acute open treatment with sertraline plus olanzapine and remain stable over the following 8 weeks will be randomized to continuing olanzapine vs. being switched to placebo. These subjects will undergo a first ("pre") MRI scan and will be rescanned ("post") at the completion of the 36-week double-blind trial or at the time of relapse. This study is innovative and unique in its use of a randomized placebo-controlled design combined with advanced neuroimaging techniques: high resolution MRI (including DTI), measurements of cortical thickness, cortical surface area, microstructural integrity of white matter tracts, and subcortical striatal and limbic morphometry. It will extend and advance conventional volumetric approaches that have been used in humans and animals to assess longitudinal effects of antipsychotics on brain structure, providing a more biologically meaningful assessment of both gray and white matter.

Public Health Relevance

Using advanced brain imaging techniques, this study will impact clinical practice by providing new evidence regarding the effects of antipsychotic medications on brain structure and connectivity. Although new evidence suggests that long-term treatment with antipsychotic medications may harm the brain, this has not been proven in a well conducted study. This unique neuroimaging study will be integrated with an ongoing federally-funded clinical trial comparing the risks and benefits of long-term treatment with sertraline plus olanzapine vs. sertraline plus placebo in patients with severe depression with delusions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH099167-02
Application #
8594263
Study Section
Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS)
Program Officer
Evans, Jovier D
Project Start
2012-12-10
Project End
2017-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
2
Fiscal Year
2014
Total Cost
$268,700
Indirect Cost
$19,904
Name
Centre for Addiction and Mental Health
Department
Type
DUNS #
207855271
City
Toronto
State
ON
Country
Canada
Zip Code
M5S2S-1
Voineskos, Aristotle N (2015) Genetic underpinnings of white matter 'connectivity': heritability, risk, and heterogeneity in schizophrenia. Schizophr Res 161:50-60
Felsky, D; Szeszko, P; Yu, L et al. (2014) The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan. Mol Psychiatry 19:1125-32
Pipitone, Jon; Park, Min Tae M; Winterburn, Julie et al. (2014) Multi-atlas segmentation of the whole hippocampus and subfields using multiple automatically generated templates. Neuroimage 101:494-512
Peters, Bart D; Voineskos, Aristotle N; Szeszko, Philip R et al. (2014) Brain white matter development is associated with a human-specific haplotype increasing the synthesis of long chain fatty acids. J Neurosci 34:6367-76
Park, Min Tae M; Pipitone, Jon; Baer, Lawrence H et al. (2014) Derivation of high-resolution MRI atlases of the human cerebellum at 3T and segmentation using multiple automatically generated templates. Neuroimage 95:217-31
Winterburn, Julie L; Pruessner, Jens C; Chavez, Sofia et al. (2013) A novel in vivo atlas of human hippocampal subfields using high-resolution 3 T magnetic resonance imaging. Neuroimage 74:254-65